Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Amylyx Pharmaceuticals, Inc. AMLX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
60/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$22.00
+28.5%

Balance sheet is a point-in-time snapshot. TTM shows the most recent available quarter.

Metric Latest Quarter (2025-12)
Total Assets $332.65M
Total Liabilities $27.39M
Total Debt $5.96M
Cash & Investments $316.98M
Total Stockholders Equity $305.26M

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.47
+0.05%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.72
+1.49%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.36
+28.30%
 MREO
MREO
Mereo BioPharma Group plc
$0.34
+2.98%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.33
+3.10%
 HOOK
HOOK
HOOKIPA Pharma Inc.
$1.11
-1.34%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message